miR expression levels in serum samples from patients with or without recurrence of early stage colon cancer (Pilot Study).

<p>Candidate miR approach. Circulating levels of 16 miRs indicated on the x-axis that had been published as differentially expressed between colon cancer and non–malignant colon tissues were analyzed <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0084686#pone.0084686-Schepeler1" target="_blank">[21]</a>, <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0084686#pone.0084686-Aslam1" target="_blank">[34]</a>, <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0084686#pone.0084686-Cheng1" target="_blank">[35]</a>. Pre-surgery serum samples were from patients in the pilot study. Patients had been followed for disease recurrence and the respective data are in Fig. 1B. <b>A</b>, Concentration of circulating miRs (relative to U6). Note the log-scale that covers a range of 100,000-fold. <b>B</b>, ratio of expression between patient groups. Alhough miR-20, miR-195 and miR-320 showed a ≥2-fold downregulation, and miR-135b and miR-615 a ≥2-fold upregulation in serum from patients with disease recurrence, neither of the comparisons reached statistical significance by ANOVA (p>0.05).